Spinal fusion surgery is a common treatment modality for various pathologic conditions of the spine, including degenerative disorders, trauma, tumours and deformities. Anterior, posterior or combined anteroposterior fusion are technically distinguished. Anterior fusion includes removal of the intervertebral disc (IVD), followed by insertion of a structural graft or spacer/cage [
1]. Additional fixation with pedicle screw/rod constructs or plating are frequently used to maintain mechanical stability until osseous fusion is reached. Although lumbar fusion is an effective clinical treatment, the prevalence of nonunion and/or pseudoarthrosis ranges between 5% and 35% [
2]. Nonunion is defined as lack of solid osseous fusion 1 year after surgery [
3]. Predictors of failure of a union are excessive motion, metabolic abnormalities, smoking, trauma and infection. Lately, clinical observations indicate that partial removal of the disc could lead to nonunion [
4,
5]. Recent studies have shown that mesenchymal stromal cells (MSCs) are prevented from undergoing osteogenesis when cocultured with IVD cells [
6,
7]. Several bone morphogenetic proteins (BMPs) are effective stimulators of osteogenesis. BMP2 and 7, which are U.S. Food and Drug Administration approved, are used in clinics as osteoinductive factors during spinal fusion [
8]. However, the applied supraphysiological doses of BMPs raise safety concerns [
9]. One essential pathway to induce osteogenic differentiation is the BMP signalling pathway [
10]. After the discovery of BMPs in 1965 by the surgeon Marshall R. Urist, many studies aimed to prove the beneficial effects of these proteins in the skeleton [
11]. BMPs bind to serotonin/threonine kinase receptors; the activated BMP receptors phosphorylate carboxyterminally the Smad 1/5/8 complex, which is then forming heteromers with Smad 4. The complex then translocates to the nucleus, where activation or inhibition activity is initiated [
12]. BMP antagonists like GREM1 (gremlin1), GREM2 (gremlin2), NOG (noggin), CHRD (hordin), FLST (follistatin), and TWSG (twisted gastrulation) bind with different affinities to BMPs, thus preventing the interaction of BMPs with their specific receptors (
Fig. 1). One possible reason for the inhibition of bone formation during spinal fusion could be the presence of different BMP antagonists, which might be secreted from remaining IVD tissue. We and others have recently shown that BMP antagonists are expressed in IVD cells [
4,
7,
13]. It has been debated whether supraphysiological doses of BMP2 should be applied in clinics. Furthermore, these high doses of BMPs often lead to adverse effects [
14]. Additionally, BMPs are known for their pleiotropic character, which means that they might induce inadvertent effects in other tissues [
15]. The BMP2 variant L51P could be a possible solution for the reduction of BMP dosis and efficacy in clinics. This analogue has one amino acid substituted with leucine to proline at position 51. L51P has a lower affinity to BMPR type I (BMPRI) but binds to BMPR type II (BMPRII) with similar affinity as does wild-type BMP2 [
16,
17]. The affinity for binding to the BMP antagonists, however, remains the same as for the wild-type [
16]. Several studies have demonstrated the increased bioefficacy of exogenous and endogenous BMP2 if L51P was applied in combination in primary murine osteoblasts, MC3T3-E1, ATCDC5 and pro-myoblasts [
18-
20]. Hauser et al. [
21] have even demonstrated improved bone formation by L51P and BMP2 in an
in vivo mouse model. So far, most studies investigated the effect of BMP2 on IVD cells for regenerative purposes. It has recently been speculated that IVDs could probably demonstrate plasticity and undergo osteogenic differentiation under certain conditions or might resist to osteogenic stimuli by an unknown mechanism. Recent studies have shown chondrogenic, others even osteogenic, differentiation of IVD cells if stimulated with BMP2 [
22]. However, our group demonstrated an apparent deblocking effect of L51P in the case of MSCs in coculture with IVD cells [
7]. Thus, this study aimed to investigate whether exogenous stimulation of L51P and BMP2 has a stimulating effect on metabolism, gene expression and extracellular matrix (ECM) production on 3 different IVD cells, that is, nucleus pulposus cells (NPCs), annulus fibrosus cells (AFCs), and cartilaginous endplate cells (CEPCs).